ATE190352T1 - Dorsalgewebe beeinflussender faktor und zusammensetzungen - Google Patents

Dorsalgewebe beeinflussender faktor und zusammensetzungen

Info

Publication number
ATE190352T1
ATE190352T1 AT93921339T AT93921339T ATE190352T1 AT E190352 T1 ATE190352 T1 AT E190352T1 AT 93921339 T AT93921339 T AT 93921339T AT 93921339 T AT93921339 T AT 93921339T AT E190352 T1 ATE190352 T1 AT E190352T1
Authority
AT
Austria
Prior art keywords
compositions
affecting factor
tissue affecting
dorsal tissue
factors
Prior art date
Application number
AT93921339T
Other languages
English (en)
Inventor
David M Valenzuela
Richard M Harland
Nancy Y Ip
William C Smith
George D Yancopoulos
Henryk Cudny
Teresa Lamb
Anne Knecht
Original Assignee
Regeneron Pharma
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Univ California filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE190352T1 publication Critical patent/ATE190352T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT93921339T 1992-09-03 1993-09-02 Dorsalgewebe beeinflussender faktor und zusammensetzungen ATE190352T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93995492A 1992-09-03 1992-09-03
US95041092A 1992-09-23 1992-09-23
US95740192A 1992-10-06 1992-10-06
PCT/US1993/008326 WO1994005791A2 (en) 1992-09-03 1993-09-02 Dorsal tissue affecting factor and compositions

Publications (1)

Publication Number Publication Date
ATE190352T1 true ATE190352T1 (de) 2000-03-15

Family

ID=27420696

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93921339T ATE190352T1 (de) 1992-09-03 1993-09-02 Dorsalgewebe beeinflussender faktor und zusammensetzungen

Country Status (8)

Country Link
US (4) US5843775A (de)
EP (1) EP0656062B1 (de)
JP (1) JP3431153B2 (de)
AT (1) ATE190352T1 (de)
AU (1) AU676847B2 (de)
DE (1) DE69328025T2 (de)
IL (2) IL106894A0 (de)
WO (1) WO1994005791A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005791A2 (en) * 1992-09-03 1994-03-17 Regeneron Pharmaceuticals, Inc. Dorsal tissue affecting factor and compositions
US5679783A (en) * 1994-11-22 1997-10-21 The Regents Of The University Of California DNA encoding a tissue differentiation affecting factor
US6133232A (en) * 1996-06-20 2000-10-17 The Regents Of The University Of California Endoderm, cardiac and neural inducing factors
WO1998033918A1 (en) * 1997-02-05 1998-08-06 The Regents Of The University Of California Morphogenic proteins
AU736328B2 (en) * 1997-02-19 2001-07-26 Regeneron Pharmaceuticals, Inc. Morphogenic proteins
US6075007A (en) * 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
WO1999061044A1 (en) * 1998-05-28 1999-12-02 The Board Of Trustees Of The University Of Arkansas Noggin and antagonists of bone morphogenetic proteins to suppress pathologic bone resorption
US6087168A (en) 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
WO2000064460A2 (en) * 1999-04-23 2000-11-02 Sulzer Orthopedics Ltd. Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin
EP2298867A3 (de) * 2000-06-20 2013-01-16 ES Cell International Pte Ltd. Methode zur Kontrolle der Differenzierung von Embryonalen Stammzellen (ES-Zellen) durch die Kultivierung von ES-Zellen in Anwesenheit von Antagonisten des BMP-2 Signalweges
WO2002054940A2 (en) * 2001-01-12 2002-07-18 University Of Medicine & Dentistry Of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
WO2002087632A1 (en) * 2001-05-02 2002-11-07 Metaprobe, Inc. High throughput screening methods using magnetic resonance imaging agents
US20030134790A1 (en) * 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
GB2385052A (en) * 2002-02-05 2003-08-13 Leuven K U Res & Dev Treatment of spondyloarthropathies
WO2007028212A1 (en) * 2005-09-08 2007-03-15 Apollo Life Sciences Limited Noggin and chimeric molecules thereof
KR101163171B1 (ko) 2009-01-20 2012-07-19 (주)케어젠 노긴?유래 펩타이드 및 그의 용도
WO2010147803A2 (en) * 2009-06-08 2010-12-23 Regents Of The University Of Michigan Adult cerebellum-derived neural stem cells and compositions and methods for producing oligodendrocytes
JP2016530243A (ja) * 2013-07-18 2016-09-29 アン アンド ロバート エイチ．ルリー チルドレンズ ホスピタル オブ シカゴ 神経管欠損症を検出及び治療する組成物及び方法
WO2015134770A1 (en) * 2014-03-07 2015-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treating soft tissue via controlled drug release
AT521641B1 (de) * 2018-09-12 2020-07-15 Fianostics Gmbh Verfahren zur Diagnose von Lebererkrankungen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0171407B1 (de) * 1984-01-30 1993-11-18 Imperial Cancer Research Technology Limited Verbesserungen an wachstumsfaktoren
EP0218692A4 (de) * 1985-04-11 1988-03-22 Childrens Medical Center Von-willebrand-faktor.
US5030576A (en) * 1986-04-30 1991-07-09 Genentech, Inc. Receptors for efficient determination of ligands and their antagonists or agonists
US4857637A (en) * 1986-05-07 1989-08-15 Genentech, Inc. Methods and compositions for immunologically modulating growth hormone receptor activity
US5219759A (en) * 1987-04-22 1993-06-15 Chiron Corporation Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
US5177197A (en) * 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5364769A (en) * 1990-09-25 1994-11-15 Genentech, Inc. Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
ATE140966T1 (de) * 1990-09-25 1996-08-15 Genentech Inc Neuer neurotropischer faktor
AU671606B2 (en) * 1991-10-31 1996-09-05 Whitehead Institute For Biomedical Research TGF-beta type receptor cDNAs and uses therefor
WO1993009229A1 (en) * 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
WO1994005791A2 (en) * 1992-09-03 1994-03-17 Regeneron Pharmaceuticals, Inc. Dorsal tissue affecting factor and compositions

Also Published As

Publication number Publication date
IL134656A (en) 2006-12-10
DE69328025T2 (de) 2000-11-02
WO1994005791A3 (en) 1994-07-07
AU4846593A (en) 1994-03-29
IL106894A0 (en) 1994-05-30
US6277593B1 (en) 2001-08-21
JP3431153B2 (ja) 2003-07-28
US5821124A (en) 1998-10-13
AU676847B2 (en) 1997-03-27
EP0656062B1 (de) 2000-03-08
JPH08504086A (ja) 1996-05-07
WO1994005791A2 (en) 1994-03-17
US20020102643A1 (en) 2002-08-01
DE69328025D1 (de) 2000-04-13
HK1008347A1 (en) 1999-05-07
EP0656062A1 (de) 1995-06-07
US5843775A (en) 1998-12-01

Similar Documents

Publication Publication Date Title
ATE190352T1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
ATE252639T1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
FI882890L (fi) Faktor viii:c-lik molekyl med koagulationsaktivitet.
DE69739758D1 (de) Vakzine zur behandlung von lymphomen und leukämie
TR200200068T2 (tr) Nematisital triflüorobütenler
ATE328896T1 (de) Faktor viii vom schwein und hybriden
EP0709090A3 (de) Zusammensetzungen zur Behandlung von resistenten Tumoren
IL143747A0 (en) Substituted aryl or heteroarylamides having retinoid-like biological activity
SE9704546D0 (sv) Novel compounds
DK0493480T3 (da) Dehydrodidemnin B
DE3870508D1 (de) Zusammensetzung zur behandlung des haares.
NZ507350A (en) Semi-synthetic ecteinascidins and use in treatment of tumors
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
KR0180256B1 (en) Bpc peptides, their preparation and use
DE69019345D1 (de) Zusammensetzung zur behandlung von samen.
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
NO175313C (no) Joderte polymerer og deres anvendelse
IL139604A0 (en) Novel peptides
FI944563A0 (fi) Mikro-organismeja, valmistusmenetelmä ja käyttö
PE20399A1 (es) Muteina ob
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
DK0842193T3 (da) Somatostatin-analoge cykliske peptider med hæmmende aktivitet på væksthormon
CA2143442A1 (en) Dorsal tissue affecting factor and compositions
AU6722498A (en) Disubstituted biphenyloxazolines
GB9604518D0 (en) Novel compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties